DrugPatentWatch Database Preview
Hoffmann La Roche Company Profile
» See Plans and Pricing
What is the competitive landscape for HOFFMANN LA ROCHE, and when can generic versions of HOFFMANN LA ROCHE drugs launch?
HOFFMANN LA ROCHE has thirteen approved drugs.
There are twelve US patents protecting HOFFMANN LA ROCHE drugs.
There are three hundred and eight patent family members on HOFFMANN LA ROCHE drugs in fifty-three countries and twenty-nine supplementary protection certificates in sixteen countries.
Summary for Hoffmann La Roche
| International Patents: | 308 |
| US Patents: | 12 |
| Tradenames: | 11 |
| Ingredients: | 10 |
| NDAs: | 13 |
Drugs and US Patents for Hoffmann La Roche
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hoffmann La Roche | ROCEPHIN KIT | ceftriaxone sodium; lidocaine | INJECTABLE;INJECTION | 050585-006 | May 8, 1996 | DISCN | No | No | Start Trial | Start Trial | |||||
| Hoffmann La Roche | ROCEPHIN | ceftriaxone sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 050585-004 | Dec 21, 1984 | DISCN | Yes | No | Start Trial | Start Trial | |||||
| Hoffmann La Roche | ZELBORAF | vemurafenib | TABLET;ORAL | 202429-001 | Aug 17, 2011 | RX | Yes | Yes | 8,470,818 | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Hoffmann La Roche
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Hoffmann La Roche | VALCYTE | valganciclovir hydrochloride | FOR SOLUTION;ORAL | 022257-001 | Aug 28, 2009 | 6,083,953*PED | Start Trial |
| Hoffmann La Roche | XELODA | capecitabine | TABLET;ORAL | 020896-002 | Apr 30, 1998 | 4,966,891 | Start Trial |
| Hoffmann La Roche | ACCUTANE | isotretinoin | CAPSULE;ORAL | 018662-002 | May 7, 1982 | 4,200,647 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for HOFFMANN LA ROCHE drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 450 mg | ➤ Subscribe | 2005-12-27 |
| ➤ Subscribe | Injection | 1 mg/mL, 3 mL Vial | ➤ Subscribe | 2007-08-31 |
| ➤ Subscribe | Tablets | 150 mg and 500 mg | ➤ Subscribe | 2008-11-10 |
| ➤ Subscribe | For Oral Solution | 50 mg/mL | ➤ Subscribe | 2011-03-21 |
| ➤ Subscribe | Tablets | 2.5 mg and 150 mg | ➤ Subscribe | 2007-05-16 |
Premature patent expirations for HOFFMANN LA ROCHE
Expiration due to failure to pay maintenance fee
| Patent Number | Expiration Date |
|---|---|
| Start Trial | Start Trial |
International Patents for Hoffmann La Roche Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Spain | 2532393 | Start Trial |
| Argentina | 039978 | Start Trial |
| Taiwan | I341730 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Hoffmann La Roche Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1893612 | PA2012010,C1893612 | Lithuania | Start Trial | PRODUCT NAME: VEMURAFENIBUM; REGISTRATION NO/DATE: EU/1/12/751/001 20120217 |
| 1893612 | SPC/GB12/021 | United Kingdom | Start Trial | PRODUCT NAME: VEMURAFENIB AND PHARMACEUTICALLY ACCEPTABLE SALTS; REGISTERED: UK EU/1/12/751/001 20120221 |
| 1893612 | C300534 | Netherlands | Start Trial | PRODUCT NAME: VEMURAFENIB ALSMEDE FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/12/751/001 20120217 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
